United Capital Financial Advisers LLC boosted its stake in Zoetis Inc (NYSE:ZTS) by 57.0% in the 2nd quarter, Holdings Channel reports. The firm owned 23,127 shares of the company’s stock after buying an additional 8,401 shares during the quarter. United Capital Financial Advisers LLC’s holdings in Zoetis were worth $2,608,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Glassman Wealth Services increased its holdings in Zoetis by 306.5% in the 1st quarter. Glassman Wealth Services now owns 252 shares of the company’s stock valued at $25,000 after purchasing an additional 190 shares in the last quarter. JJJ Advisors Inc. acquired a new stake in Zoetis in the 2nd quarter valued at $25,000. Altshuler Shaham Ltd increased its holdings in Zoetis by 198.8% in the 2nd quarter. Altshuler Shaham Ltd now owns 254 shares of the company’s stock valued at $29,000 after purchasing an additional 169 shares in the last quarter. Next Capital Management LLC increased its holdings in Zoetis by 156.5% in the 2nd quarter. Next Capital Management LLC now owns 295 shares of the company’s stock valued at $33,000 after purchasing an additional 180 shares in the last quarter. Finally, Destination Wealth Management increased its holdings in Zoetis by 217.9% in the 2nd quarter. Destination Wealth Management now owns 337 shares of the company’s stock valued at $38,000 after purchasing an additional 231 shares in the last quarter. Hedge funds and other institutional investors own 90.09% of the company’s stock.
Several brokerages recently issued reports on ZTS. Guggenheim began coverage on Zoetis in a report on Thursday, May 23rd. They issued a “buy” rating and a $114.00 price target for the company. Credit Suisse Group reissued a “buy” rating and set a $130.00 target price on shares of Zoetis in a research note on Wednesday, September 11th. Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 target price (up previously from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Bank of America lowered shares of Zoetis from a “buy” rating to a “neutral” rating and lifted their target price for the company from $111.00 to $120.00 in a research note on Monday, July 1st. They noted that the move was a valuation call. Finally, Goldman Sachs Group assumed coverage on shares of Zoetis in a research note on Monday, September 9th. They set a “conviction-buy” rating and a $145.00 target price for the company. Seven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $120.94.
Shares of ZTS stock traded down $0.39 on Wednesday, hitting $122.03. The company’s stock had a trading volume of 909,470 shares, compared to its average volume of 1,957,003. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.87. Zoetis Inc has a fifty-two week low of $78.90 and a fifty-two week high of $130.08. The firm’s fifty day moving average price is $123.31 and its 200-day moving average price is $109.46. The stock has a market capitalization of $58.38 billion, a price-to-earnings ratio of 38.99, a P/E/G ratio of 3.06 and a beta of 0.86.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.08. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.51 billion. During the same quarter in the previous year, the business earned $0.77 EPS. Zoetis’s quarterly revenue was up 9.3% compared to the same quarter last year. Analysts predict that Zoetis Inc will post 3.57 EPS for the current fiscal year.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.